We are live on ! Find out more
NVAX icon

Novavax

167 hedge funds and large institutions have $290M invested in Novavax in 2018 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 41 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more call options, than puts

Call options by funds: $13.1M | Put options by funds: $4.98M

33% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 21

29% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 41

4% more funds holding

Funds holding: 160167 (+7)

0.01% more ownership

Funds ownership: 2.05%2.06% (+0.01%)

2% less capital invested

Capital invested by funds: $295M → $290M (-$4.43M)

Holders
167
Holders Change
+7
Holders Change %
+4.38%
% of All Funds
3.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
28
Increased
53
Reduced
41
Closed
21
Calls
$13.1M
Puts
$4.98M
Net Calls
+$8.12M
Net Calls Change
+$7.73M

NVAX Hedge Fund Activity: Q4 2018 in Review

167 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q4 2018, worth a combined $290M — down 1.5% from $295M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NVAX positions and 21 closed out — a net gain of 7 holders — while 53 added to existing stakes and 41 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $5.45M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $5.62M sold.

  • 167 institutional investors held Novavax (NVAX) as of Q4 2018, up from 160 in Q3 2018.
  • Funds reported $290M of Novavax stock for Q4 2018, down 1.5% quarter-over-quarter.
  • 28 funds opened new Novavax positions in Q4 2018 and 21 closed out, a net change of +7 holders.
  • The largest Novavax buyer in Q4 2018 was T. Rowe Price Associates, an estimated $5.45M added.
  • The largest Novavax seller in Q4 2018 was Pictet Asset Management (UK), an estimated $5.62M sold.

Based on aggregated 13F filings for Q4 2018.